
NYSEHealthcareMedical - Devices
ข้อมูลล่าสุด
US$118.69
−US$0.78 · -0.65%
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
ข้อมูลล่าสุด
US$118.69
−US$0.78 · -0.65%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ซื้อ
มูลค่า
76
ต่ำกว่ามูลค่า
ความเชื่อมั่น
61
เชิงบวก
ความเสี่ยง
30
ความเสี่ยงปานกลาง
โมเมนตัม
52
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2026 | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 |
|---|---|---|---|---|---|
| รายได้ | 1.33B USD | 1.36B USD | 1.31B USD | 1.17B USD | 993.2M USD |
| ต้นทุนสินค้าขาย | 590.44M USD | 582.28M USD | 597.14M USD | 545.79M USD | 462.43M USD |
| กำไรขั้นต้น | 743.59M USD | 778.55M USD | 711.92M USD | 622.87M USD | 530.77M USD |
| การวิจัยและพัฒนา | 59.77M USD | 69.42M USD | 63.04M USD | 58.63M USD | 55.2M USD |
| การขาย ทั่วไป และธุรการ | 442.42M USD | 422.05M USD | 420.82M USD | 373.95M USD | 332.2M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 502.19M USD | 556.73M USD | 547.03M USD | 466.84M USD | 450.02M USD |
| ดอกเบี้ยจ่าย | 28.7M USD | 9.75M USD | 13.02M USD | 14.63M USD | 17.12M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 111.72M USD | 115.59M USD | 97.22M USD | 93.31M USD | 97.75M USD |
| รายได้จากการดำเนินงาน | 241.4M USD | 221.82M USD | 164.88M USD | 156.03M USD | 80.75M USD |
| รายได้สุทธิ | 97.31M USD | 167.68M USD | 117.56M USD | 115.4M USD | 43.38M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 11 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$130.8
โอกาสปรับขึ้น 10.20%ไม่มีประวัติราคา
สูง: US$140เฉลี่ย: US$130.8ต่ำ: US$119กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Vanguard Morningstar Total Stock Market ETFVTI148.96M0.01%2.3T USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM145.06M0.19%78.74B USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB107.76M0.06%185.3B USD0.03%US$289.48+0.64%
Vanguard Extended Market ETFVXF55.66M0.06%95.4B USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO47.99M0.35%13.92B USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS42.14M0.12%33.87B USD0.31%US$78.35+0.32%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY40.38M0.16%25.82B USD0.23%US$669.87+0.54%
Vanguard Morningstar Small-Cap Value ETFVBR34.22M0.05%68.2B USD0.05%US$234.43+0.22%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
Vanguard Morningstar Small-Cap Value ETFVBRเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน